COVID-19 UPDATE: All elective surgeries and procedures are cancelled until further notice. Please see our latest visitor policy. If you think you may have been exposed or have symptoms, please call your provider before visiting one of our locations. For more information, please visit our online COVID-19 Information Center or call the Montefiore-Einstein COVID-19 Hotline: 1-844-444-CV19 (1-844-444-2819).

ACTUALIZACIÓN SOBRE EL COVID-19: Todas las cirugías y operaciones quedan canceladas hasta nuevo aviso. Lea nuestras nuevas normas para visitas. Si cree que podría haber estado en contacto con la enfermedad o si presenta síntomas, por favor llame a su proveedor antes de acudir a cualquiera de nuestros centros. Más información en nuestro Centro de Información en Línea sobre el COVID-19 o llamando a la línea informativa Montefiore-Einstein de COVID-19: 1-844-444-CV19 (1-844-444-2819).

Familial Neuroendocrine Syndromes
Home >  Cancer (Oncology) >  Diseases and Conditions >  Endocrine/Neuroendocrine Tumors >  Familial Neuroendocrine Syndromes

Diseases and Conditions

Familial Neuroendocrine Syndromes

Familial endocrine syndromes are caused by genetic mutations that can be passed through families from generation to generation. Some types of neuroendocrine tumors are found much more frequently in patients with these genetic mutations. Genetic testing can help identify and treat patients and their families, and can prevent complications from advanced neuroendocrine tumors. The most common familial neuroendocrine syndromes are outlined below with their respective genetic mutations and the types of tumors found in these patients.

Multiple Endocrine Neoplasia Type I (MENI)

MENI is a genetic mutation of the menin gene, which plays a role in suppressing tumor formation. Patients with MENI are at increased risk for developing pituitary tumors, pancreatic neuroendocrine tumors and hyperparathyroidism.

Multiple Endocrine Neoplasia Type IIa (MENIIa)

MENIIa is a genetic mutation of the RET proto-oncogene, which increases a patient's risk for developing medullary thyroid cancer, hyperparathyroidism and pheochromocytoma.

Multiple Endocrine Neoplasia Type IIb (MENIIb)

MENIIb is also a genetic mutation of the RET proto-oncogene, which increases a patient's risk for developing medullary thyroid cancer at a very young age, as well as pheochromocytoma and mucosal neuromas of the lips, tongue and eyelids.

Von Hipple-Lindau

Patients with the von Hipple-Lindau disease mutation have an increased risk of developing pheochromocytomas, central nervous system hemangioblastomas, kidney tumors, pancreatic neuroendocrine tumors and retinal tumors.

SDH Mutations

Succinate dehydrogenase (SDH) is an enzyme that is important for the metabolic function of mitochondria. Patients with SDH mutations have an increased risk of pheochromocytomas, paragangliomas, stomach tumors and kidney tumors.

Treatment of Familial Neuroendocrine Syndromes

Patients and their families who have been diagnosed with familial neuroendocrine syndromes require care across several different medical specialties, including genetics, medicine, surgery, oncology and radiology. The multidisciplinary approach of a neuroendocrine tumor program can address all aspects of innovative and technologically advanced care.